VIP (Vasoactive Intestinal Peptide) Research Evidence
The VIP (Vasoactive Intestinal Peptide) evidence base: trials, journals, and what the data does not yet show.
Well-Characterized Physiology, Limited Modern Trials
VIP's core physiology — vasodilation, bronchodilation, immune modulation — is well established from decades of basic-science and pharmacology research. However, its use as a therapeutic research compound for specific conditions (chronic inflammatory response, mold-illness protocols) rests on a much thinner and less rigorously controlled human evidence base.
Regulatory and Legal Status
VIP itself has no FDA-approved indication and is not approved for human consumption in the peptide-vendor research-chemical form sold to consumers. (Note: a related but chemically distinct VIP-based drug, aviptadil, has been separately studied for other indications — that is not the same product as research-grade VIP peptide.) It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of VIP in their jurisdiction prior to purchase or use.